Plasma PF4 is a reliable biomarker of platelet reactivity and predictive of bleeding risk in DAPT patients undergoing cardiac surgery
Joseph Roux de Bezieux, Julien Amour, Aurélien Philippe, Jeanne Rancic, Nicolas Gendron, Sébastien Bertil, Marc Garnier, Pascale Gaussem, David M Smadja · 2026
Read Plasma PF4 is a reliable biomarker of platelet reactivity and predictive of bleeding risk in DAPT patients undergoing cardiac surgery by Joseph Roux de Bezieux, Julien Amour, Aurélien Philippe, Jeanne Rancic, Nicolas Gendron, Sébastien Bertil, Marc Garnier, Pascale Gaussem, David M Smadja (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13235088.txt.
Description
Joseph Roux de Bezieux and colleagues searched in 2026 for a blood marker that predicts bleeding during heart bypass surgery. Patients often take two antiplatelet drugs together until surgery, which raises bleeding concern. Four platelet-related proteins were measured in one hundred forty-three patients before their operations. Standard platelet function tests and later blood loss from chest drains provided comparisons.
Two proteins, called PF4 and NAP-2, ran much lower in patients on dual therapy than on aspirin alone. Their levels matched several laboratory measures of platelet reactivity in the study. Levels of both proteins also related independently to blood lost during the first day after surgery. The other two proteins showed no useful links to outcomes or test results. The authors name PF4 as the most platelet-specific candidate for guiding care around surgery.
Catalog record
| CREATOR | Joseph Roux de Bezieux, Julien Amour, Aurélien Philippe, Jeanne Rancic, Nicolas Gendron, Sébastien Bertil, Marc Garnier, Pascale Gaussem, David M Smadja |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |